Product Pathways - Glucose Metabolism
IGFBP-2 Antibody #3922
| Applications | Reactivity | Sensitivity | MW (kDa) | Source |
|---|---|---|---|---|
| W IP IHC-P | H | Endogenous | 35 | Rabbit |
Applications Key:
W=Western Blotting
IP=Immunoprecipitation
IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:
H=Human
Species cross-reactivity is determined by Western blot.
Specificity / Sensitivity
IGFBP-2 Antibody detects endogenous levels of total IGFBP-2 protein. It does not cross-react with other IGFBP family members.
Source / Purification
Polyclonal antibodies are produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to the residues at the carboxy-terminal sequence of human IGFBP-2. The antibodies are purified by protein A and peptide affinity chromatography.
Western Blotting
Western blot analysis of human serum and extracts from various cell lines, using IGFBP-2 Antibody.
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, showing cytoplasmic localization, using IGFBP-2 Antibody.
Background
Insulin-like growth factor-binding proteins (IGFBPs) play an integral role in modifying insulin-like growth factor (IGF) actions in a wide variety of cell types. This family contains six members that are structurally related but encoded by distinct genes. IGFBPs have a high affinity for IGFs. Some members of the IGFBP family have been consistently shown to inhibit IGF actions by preventing them from gaining access to the IGF receptors, while others potentiate IGF actions by facilitating the ligand-receptor interaction (1-3). IGFBP-2 is the second most abundant IGFBP in the circulation and is present in various other biological fluids and tissues of many vertebrate species. Serum IGFBP-2 levels are elevated in conditions such as shock, fasting, hypoxemia or after traumata, suggesting complex regulation of IGFBP-2 expression (4). IGFBP-2 is overexpressed in many malignancies and is often correlated with an increasingly malignant status of the tumor, pointing to a potential involvement of IGFBP-2 in tumorigenesis (5).
- Duan, C. (2002) J. Endocrinol. 175, 41-54.
- Sandhu, M. S. et al. (2002) J. Natl. Cancer Inst. 94, 972-980.
- Baxter, R.C. (2001) Best Pract. Res. Clin. Endocrinol. Metab. 15, 421-434.
- Noel, M. et al. (2001) Curr. Opin. Clin. Nutr. Metab. Care 4, 399-405.
- Zumkeller, W. (2001) Mol. Pathol. 54, 285-288.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 3021 Phospho-IGF-I Receptor β (Tyr1131)/Insulin Receptor β (Tyr1146) Antibody
- 3024 Phospho-IGF-I Receptor β (Tyr1135/1136)/Insulin Receptor β (Tyr1150/1151) (19H7) Rabbit mAb
- 3027 IGF-I Receptor β Antibody
- 3018 IGF-I Receptor β (111A9) Rabbit mAb
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.
